1. Home
  2. BYAH vs OGEN Comparison

BYAH vs OGEN Comparison

Compare BYAH & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Ha Biological Technology Co. Ltd. Ordinary Shares

BYAH

Park Ha Biological Technology Co. Ltd. Ordinary Shares

N/A

Current Price

$2.17

Market Cap

1.9M

ML Signal

N/A

Logo Oragenics Inc.

OGEN

Oragenics Inc.

N/A

Current Price

$0.35

Market Cap

2.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BYAH
OGEN
Founded
2016
1996
Country
China
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9M
2.2M
IPO Year
2023
2010

Fundamental Metrics

Financial Performance
Metric
BYAH
OGEN
Price
$2.17
$0.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
11.8K
★ 18.6K
Earning Date
07-24-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.35
52 Week High
$6.64
$1.22

Technical Indicators

Market Signals
Indicator
BYAH
OGEN
Relative Strength Index (RSI) 46.35 27.74
Support Level $1.97 N/A
Resistance Level $3.26 $0.59
Average True Range (ATR) 0.16 0.02
MACD -0.01 -0.00
Stochastic Oscillator 43.97 5.83

Price Performance

Historical Comparison
BYAH
OGEN

About BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares

Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales, and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha, in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complementary after-sales beauty services in its physical stores.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: